ArticleThe Journal of clinical investigation2011
FGF23 induces left ventricular hypertrophy.
Article in The Journal of clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 1,056 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Cohort Study of Chronic Renal Insufficiency
New Biomarkers in Heart- and Renal Failure: Cohort Study for Assessing Prognosis in Acute Coronary Syndrome and Acute/Chronic Cardiovascular and Renal Failure by Means of Fibroblast Growth Factor 23
Interplay of FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)
Time Course of Circulating Myocardial Biomarkers After a TASH Procedure.
"Exploration of the Role of Intact Fibroblast Growth Factor 23 and Its C-terminal Fragment in Chronic Respiratory Failure "
Who cites it
1,056 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,972 citations in OpenAlex.
- Pooled it
- Vitamin D in the prevention of left ventricular remodelling after an acute myocardial infarction: a randomized clinical trial.Scientific reports · 2026Trial
- Controlled dietary phosphate loading in healthy young men elevates plasma phosphate and FGF23 levels.Pflugers Archiv : European journal of physiology · 2025Trial
- The effect of intradialytic exercise on calcium, phosphorus and parathyroid hormone: a randomized controlled trial.BMC nephrology · 2023Trial
- Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.International urology and nephrology · 2023Trial
- FGF23 promotes atrial fibrillation susceptibility through ETV1-dependent sodium channel regulation and calcium handling abnormalities.Experimental physiology · 2026Article
- Tenapanor Beyond Phosphate: Gut Sodium Transport, Stool Transit Time, and Volume Balance in Dialysis Patients.Hemodialysis international. International Symposium on Home Hemodialysis · 2026Review
- The Binding of Fibroblast Growth Factor 23 (FGF23) to FGF Receptor-αKlotho Complex Increases Sinoatrial Electrical Activity.Acta physiologica (Oxford, England) · 2026Article
- Cardiovascular Disease in CKD: Ethnic and Regional Differences in Risk and Phenotype.Clinical journal of the American Society of Nephrology : CJASN · 2026Review
- Fibroblast Growth Factor 23 and Outcomes in Acute Heart Failure.Biomolecules · 2026Article
- Utility of Risk Scores for Predicting Stroke and Intracranial Bleeding Across Levels of Kidney Function in Two Large Community-Based Cohorts of Older Adults With Atrial Fibrillation.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026Article
- Unraveling the Metabolic-Cardiovascular Disease Nexus: An Epidemiological Network Analysis Identifies Central Indicators.MedComm · 2026Article
- Intravenous ferric carboxymaltose and exercise capacity in iron-deficient kidney transplant recipients: a randomised, placebo-controlled trial in the Netherlands.EClinicalMedicine · 2026Article
- Review
- FGF23 - A hormone produced by bone and has many faces.Reviews in endocrine & metabolic disorders · 2026Review
- Beyond Bone Health: Exploring the "Heart-Brain-Bone" Axis Modulated by Lipid-Soluble Nutrients (Omega-3, Vitamin D3, and Vitamin K2).Nutrients · 2026Review
- Profile of FGF23 and NTproBNP levels and their association with left ventricular hypertrophy in children and adolescents with CKD.International urology and nephrology · 2026Article
- Estrogen protects female mice with chronic kidney disease from fibroblast growth factor 23-induced left ventricular hypertrophy.Kidney international · 2026Article
- Beyond eGFR and Albuminuria: Biological Pathways and Multiomics in Cardiovascular-Kidney-Metabolic Disease.Kidney international reports · 2026Review
- Unraveling the dual role of fibroblast growth factor 5 (FGF5) in cardiorenal diseases through multi-omics causal inference.Cardiovascular diabetology · 2026Observational
996 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 12 institutions in 2 countries.
Funding
Abstract
Chronic kidney disease (CKD) is a public health epidemic that increases risk of death due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiovascular disease in individuals with CKD. Elevated levels of FGF23 have been linked to greater risks of LVH and mortality in patients with CKD, but whether these risks represent causal effects of FGF23 is unknown. Here, we report that elevated FGF23 levels are independently associated with LVH in a large, racially diverse CKD cohort. FGF23 caused pathological hypertrophy of isolated rat cardiomyocytes via FGF receptor-dependent activation of the calcineurin-NFAT signaling pathway, but this effect was independent of klotho, the coreceptor for FGF23 in the kidney and parathyroid glands. Intramyocardial or intravenous injection of FGF23 in wild-type mice resulted in LVH, and klotho-deficient mice demonstrated elevated FGF23 levels and LVH. In an established animal model of CKD, treatment with an FGF-receptor blocker attenuated LVH, although no change in blood pressure was observed. These results unveil a klotho-independent, causal role for FGF23 in the pathogenesis of LVH and suggest that chronically elevated FGF23 levels contribute directly to high rates of LVH and mortality in individuals with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.